ForeverLabs
0%
ClinicalHeart DiseaseHeart Disease

Ixmyelocel-T for patients with ischaemic heart failure: a prospective randomised double-blind trial

PubMed

Key Findings

This was a prospective, randomized, double-blind, placebo-controlled trial - which is considered the gold standard for clinical research.

Patients used their own stem cells to regenerate damaged heart muscle whose heart failure was caused by blocked coronary arteries (ischemic), showing fewer heart-related complications and better symptoms compared to placebo.

AI generated image for: Ixmyelocel-T for patients with ischaemic heart failure: a prospective randomised double-blind trial

This was a prospective, randomized, double-blind, placebo-controlled trial - which is considered the gold standard for clinical research. Patients used their own stem cells to regenerate damaged heart muscle whose heart failure was caused by blocked coronary arteries (ischemic), showing fewer heart-related complications and better symptoms compared to placebo.

Ready to learn more?

Subscribe to our newsletter and book your free, 15-minute consultation with Forever Labs today.

Research Details

Source

PubMed

Publication Date
Categories & Tags
ClinicalHeart DiseaseHeart Disease
View Original Publication

Cite this article: PubMed. "Ixmyelocel-T for patients with ischaemic heart failure: a prospective randomised double-blind trial". Published August 11, 2025. Available at: https://pubmed.ncbi.nlm.nih.gov/27059887/

Access Original Research

View the complete study and detailed methodology from the original source.

Read Full Study↗
← All Articles← Clinical Articles

You Might Also Like

Explore more articles in this category

AI generated image for: Autologous hematopoietic stem cell transplantation in multiple sclerosis: a phase II trial
1 min

Autologous hematopoietic stem cell transplantation in multiple sclerosis: a phase II trial

This phase II randomized trial demonstrates that autologous hematopoietic stem cell transplantation (AHSCT) is significantly more effective than mitoxantrone at reducing MRI-detected disease activity in patients with aggressive multiple sclerosis. Results showed a 79% reduction in new T2 lesions and a significant decrease in relapse rates, supporting the need for larger phase III clinical trials.

Neurology
AI generated image for: Effect of aging on stem cells
1 min

Effect of aging on stem cells

As we age, stem cells lose efficacy and ability to heal.

NIH
AI generated image for: Intravenous transplantation of bone marrow-derived mononuclear cells prevents memory impairment in transgenic mouse models of Alzheimer's disease
1 min

Intravenous transplantation of bone marrow-derived mononuclear cells prevents memory impairment in transgenic mouse models of Alzheimer's disease

Intravenous transplantation of bone marrow-derived mononuclear cells (BMMCs) successfully improved cognitive function and prevented neurodegeneration in two different Alzheimer's disease mouse models.

PubMed